Bayer Kogenate FS
Bayer HealthCare, Biological Products Division

Contact Search Press Sitemap  
HomePatients & CaregiversHealthcare ProfessionalsPrescribing Information
Kogenate FS
Prescribing Information
Important Safety Information
Patient Video
EZ-Log
Bayer Factor Solutions
Kogenate Connections
Summer Camps
Hemophilia Awards
PEP
Rep Finder
Living with Hemophilia
En Español
Bayer Links
Bayer Global
Living with Hemophilia
   General Conditions of Use
Privacy Statement
Imprint
  
 
  

Kogenate® FS, Antihemophilic Factor (Recombinant), Formulated with Sucrose

In the early 1970s, we introduced our first factor VIII (FVIII) product for patients with hemophilia A. Since that time, we have been dedicated to enhancing the safety, simplicity, and efficacy of hemophilia treatments.

We are pleased to provide this website as part of our ongoing effort to supply the bleeding disorders community with the latest in product information, important news, associated support programs, and resources.





Join Now!
Join our mailing list. It's simple and fast.
Join Now


 
  

Kogenate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness, and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. For important safety and use information, please see the full prescribing information.

Please consult your health care provider prior to making any lifestyle changes. The images used on this site do not necessarily represent actual Hemophilia patients.